Tower Research Capital LLC TRC Has $31,000 Stock Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX)

Tower Research Capital LLC TRC boosted its position in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) by 998.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 4,130 shares of the company’s stock after purchasing an additional 3,754 shares during the period. Tower Research Capital LLC TRC’s holdings in Avalo Therapeutics were worth $31,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of AVTX. Geode Capital Management LLC boosted its position in Avalo Therapeutics by 937.0% during the fourth quarter. Geode Capital Management LLC now owns 104,853 shares of the company’s stock valued at $779,000 after purchasing an additional 94,742 shares during the last quarter. Bank of Montreal Can acquired a new stake in Avalo Therapeutics during the fourth quarter valued at $446,000. Walleye Capital LLC acquired a new stake in Avalo Therapeutics during the fourth quarter valued at $145,000. Affinity Asset Advisors LLC boosted its position in Avalo Therapeutics by 1,123.9% during the fourth quarter. Affinity Asset Advisors LLC now owns 550,765 shares of the company’s stock valued at $4,092,000 after purchasing an additional 505,765 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Avalo Therapeutics during the fourth quarter valued at about $114,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Trading Up 7.2%

Avalo Therapeutics stock opened at $3.86 on Friday. The business’s 50-day simple moving average is $5.86 and its 200-day simple moving average is $7.90. Avalo Therapeutics, Inc. has a 52 week low of $3.39 and a 52 week high of $16.00.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Monday, May 12th. The company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.18). As a group, research analysts predict that Avalo Therapeutics, Inc. will post -19.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on AVTX. Jefferies Financial Group began coverage on Avalo Therapeutics in a report on Tuesday, March 25th. They set a “buy” rating and a $23.00 target price on the stock. HC Wainwright restated a “neutral” rating on shares of Avalo Therapeutics in a report on Thursday, March 20th. Stifel Nicolaus began coverage on Avalo Therapeutics in a report on Tuesday, March 25th. They set a “buy” rating and a $36.00 target price on the stock. Wedbush restated an “outperform” rating and set a $18.00 target price on shares of Avalo Therapeutics in a report on Thursday, March 20th. Finally, Piper Sandler assumed coverage on Avalo Therapeutics in a report on Friday, February 28th. They set an “overweight” rating and a $48.00 target price on the stock. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $33.00.

Avalo Therapeutics Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.